Abstract
Few pharmacological intervention studies have examined the impact of medication on social cognition, particularly emotion perception. The goal of this randomized, double-blind study is to compare the effects of several second generation antipsychotics and a first generation antipsychotic, perphenazine, on emotion perception in individuals with schizophrenia. Patients were assigned to receive treatment with olanzapine, queitapine fumarate, risperidone, ziprasidone or perphenazine for up to 18 months. Eight hundred and seventy three patients completed an emotion perception test immediately prior to randomization and after 2 months of treatment. We also examined baseline predictors of emotion perception change. Most treatments were associated with a small, non-statistically significant improvement in emotion perception at two months, although they did not differ from one another. Greater improvement in emotion perception at 2 months was significantly predicted by lower baseline emotion perception and higher baseline neurocognitive functioning, and marginally predicted by less time on an antipsychotic.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 17-23 |
| Number of pages | 7 |
| Journal | Schizophrenia Research |
| Volume | 115 |
| Issue number | 1 |
| DOIs | |
| State | Published - Nov 2009 |
| Externally published | Yes |
Bibliographical note
Funding Information:This article was based on results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project, supported by the National Institute of Mental Health (NO1 MH-90001). Medications for the study were provided by AstraZeneca Pharmaceuticals L.P., Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Pharmaceuticals, Inc., Janssen Pharmaceutica Products, L.P., Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., and Zenith Goldline Pharmaceuticals, Inc.
Keywords
- Antipsychotic
- Emotion perception
- Pharmacological treatment
- Schizophrenia
- Social cognition